Continuous Tralokinumab Treatment over 4 Years in Adults With Moderate-to-Severe Atopic Dermatitis Provides Long-Term Disease Control. J of Skin 2024, 8 (2), s376. https://doi.org/10.25251/skin.8.supp.376.